MX2010004953A - Formulaciones de solucion oftalmica u otica topicas que contienen clorihidrato de moxifloxacina y fosfato de dexametasona. - Google Patents

Formulaciones de solucion oftalmica u otica topicas que contienen clorihidrato de moxifloxacina y fosfato de dexametasona.

Info

Publication number
MX2010004953A
MX2010004953A MX2010004953A MX2010004953A MX2010004953A MX 2010004953 A MX2010004953 A MX 2010004953A MX 2010004953 A MX2010004953 A MX 2010004953A MX 2010004953 A MX2010004953 A MX 2010004953A MX 2010004953 A MX2010004953 A MX 2010004953A
Authority
MX
Mexico
Prior art keywords
formulations containing
topical ophthalmic
dexamethasone phosphate
solution formulations
moxifloxacin hydrochloride
Prior art date
Application number
MX2010004953A
Other languages
English (en)
Inventor
Suresh C Dixit
Michael Wallach
Onkar N Singh
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of MX2010004953A publication Critical patent/MX2010004953A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen las composiciones de solución oftálmica y ótica tópicas de moxifloxacina y fosfato de dexametasona.
MX2010004953A 2007-11-27 2008-11-24 Formulaciones de solucion oftalmica u otica topicas que contienen clorihidrato de moxifloxacina y fosfato de dexametasona. MX2010004953A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99045207P 2007-11-27 2007-11-27
PCT/US2008/084532 WO2009070530A1 (en) 2007-11-27 2008-11-24 Topical ophthalmic or otic solution formulations containing moxifloxacin hydrochloride and dexamethasone phosphate

Publications (1)

Publication Number Publication Date
MX2010004953A true MX2010004953A (es) 2010-08-10

Family

ID=40467276

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004953A MX2010004953A (es) 2007-11-27 2008-11-24 Formulaciones de solucion oftalmica u otica topicas que contienen clorihidrato de moxifloxacina y fosfato de dexametasona.

Country Status (16)

Country Link
US (2) US7888370B2 (es)
EP (1) EP2211835A1 (es)
JP (1) JP2011504881A (es)
KR (1) KR20100090278A (es)
CN (1) CN101861139A (es)
AR (1) AR069438A1 (es)
AU (1) AU2008329876A1 (es)
BR (1) BRPI0819908A2 (es)
CA (1) CA2703913A1 (es)
CL (1) CL2008003536A1 (es)
MX (1) MX2010004953A (es)
RU (1) RU2010126096A (es)
TW (1) TW200932285A (es)
UY (1) UY31494A1 (es)
WO (1) WO2009070530A1 (es)
ZA (1) ZA201002884B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220431B2 (en) 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
WO2013065029A1 (en) * 2011-11-04 2013-05-10 Micro Labs Limited Fixed dose combination containing moxifloxacin and prednisolone for treatment of ocular infections
ITMI20122002A1 (it) * 2012-11-26 2014-05-27 Farmacologico Milanese Srl Lab Preparazioni farmaceutiche liquide stabilizzate
CA2899237A1 (en) 2013-01-31 2014-08-07 Senju Pharmaceutical Co., Ltd. Clear aqueous solution
US20160279055A1 (en) 2013-07-22 2016-09-29 Imprimis Pharmaceuticals, Inc. Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
US20150164882A1 (en) 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US11452732B2 (en) * 2015-09-05 2022-09-27 Randal Davis Homogeneous ophthalmic composition
US10130639B1 (en) * 2015-09-05 2018-11-20 Randal Davis Homogeneous ophthalmic composition
GR1008921B (el) * 2015-12-10 2017-01-12 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση περιεχον δεξαμεθαζονη
KR20190109604A (ko) * 2016-05-06 2019-09-25 해로우 헬스 인코포레이티드 약학적 안과용 조성물 및 그의 제조 방법
US20190216830A1 (en) * 2017-10-06 2019-07-18 Aciont Inc. Ophthalmic compositions
CN113750041A (zh) * 2020-06-04 2021-12-07 成都倍特药业股份有限公司 一种地塞米松磷酸钠液体制剂及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2939873A (en) * 1959-01-26 1960-06-07 Merck & Co Inc Synthesis of steroid phosphates
US5414011A (en) * 1987-09-11 1995-05-09 Syntex (U.S.A.) Inc. Preservative system for ophthalmic formulations
US5407926A (en) * 1987-12-29 1995-04-18 Alcon Laboratories, Inc. Ophthalmic composition
DE3906365A1 (de) * 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
US5397771A (en) * 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
IL102414A (en) * 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
ES2079994B1 (es) * 1992-10-07 1996-08-01 Cusi Lab Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
US6740664B2 (en) * 1998-09-30 2004-05-25 Alcon, Inc. Methods for treating otic and ophthalmic infections
US6716830B2 (en) * 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
WO2001089495A2 (en) 2000-05-19 2001-11-29 Alcon Laboratories, Inc. Antibiotic compositions containing quinolone derivatives for treatment of the eye, ear and nose

Also Published As

Publication number Publication date
CN101861139A (zh) 2010-10-13
US7888370B2 (en) 2011-02-15
WO2009070530A1 (en) 2009-06-04
BRPI0819908A2 (pt) 2015-05-19
ZA201002884B (en) 2011-07-27
EP2211835A1 (en) 2010-08-04
RU2010126096A (ru) 2012-01-10
AR069438A1 (es) 2010-01-20
US8173671B2 (en) 2012-05-08
CA2703913A1 (en) 2009-06-04
JP2011504881A (ja) 2011-02-17
UY31494A1 (es) 2009-03-02
US20110082125A1 (en) 2011-04-07
US20090137539A1 (en) 2009-05-28
KR20100090278A (ko) 2010-08-13
CL2008003536A1 (es) 2009-10-16
AU2008329876A1 (en) 2009-06-04
TW200932285A (en) 2009-08-01

Similar Documents

Publication Publication Date Title
MX2010004953A (es) Formulaciones de solucion oftalmica u otica topicas que contienen clorihidrato de moxifloxacina y fosfato de dexametasona.
TW200626132A (en) Topical nepafenac formulations
TN2010000203A1 (en) Beta-lactamase inhibitors
PH12014500053A1 (en) Proteasome inhibitors
TW200740803A (en) Heterocyclic derivatives as modulators of ion channels
PH12014502880A1 (en) Lyophilized therapeutic peptibody formulations
MY166653A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
MY181898A (en) Heterocyclic compounds and uses thereof
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
TN2009000446A1 (en) P70 s6 kinase inhibitors
MX2019009176A (es) Formulaciones de etanercept estabilizadas con iones metalicos.
EP2271301A4 (en) METHODS AND COMPOSITIONS FOR THE DELIVERY OF AGENTS
MX2012000396A (es) Metodos y composiciones para uso en tartamientos celulares.
ZA200710332B (en) Bicyclic derivatives as modulators of ion channels
AU2008321142A8 (en) Heterocyclic derivatives as modulators of ion channels
MX2009013170A (es) Particulas de silice y metodos para prepararlas y utilizarlas.
MX2014010537A (es) Moduladores de receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dermicas.
UA105920C2 (uk) ПОХІДНІ СПОЛУК СТЕРОЇДАЛ[3,2-с]ПІРАЗОЛУ З ГЛЮКОКОРТИКОЇДНОЮ АКТИВНІСТЮ
MX2009012370A (es) Formulacion de antraciclina de baja viscosidad.
WO2009102707A3 (en) Substituted oxazaphosphorines
MX2009012643A (es) Particulas de alumina y metodos para fabricar las mismas.
MX2008002272A (es) Compuestos de ciclopropilo y composiciones para suministrar agentes activos.
EP1960415A4 (en) PHOSPHOLIPID MOLD COMPOSITIONS FOR THE ADMINISTRATION OF APTAMERES AND METHOD FOR THE TREATMENT OF SUFFERING USES THEREOF
AU2015201137B2 (en) Compositions and method for tissue preservation
WO2007095256A3 (en) Methods of promoting cardiac cell proliferation

Legal Events

Date Code Title Description
FA Abandonment or withdrawal